Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Targeting glutamine/glutamate metabolism to improve bone disease in patients with multiple myeloma

Nicola Giuliani • 26 Aug 2022
IMS 2022
Multiple Myeloma

Nicola Giuliani, MD, PhD, University of Parma, Parma, Italy, comments on the potential to target glutamine/glutamate metabolism to block osteoclast-mediated bone destruction and improve bone disease in patients with multiple myeloma, highlighting data from in vitro experiments. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicola Giuliani

1:32
Impact of impaired glutamine/glutamate metabolic axis on osteoclast activation in multiple myeloma
Nicola Giuliani • 26 Aug 2022
2:48
Glutamine metabolism as a diagnostic tool for bone disease in patients with multiple myeloma
Nicola Giuliani • 26 Aug 2022
3:40
Clonal evolution in MM: MGUS and SMM
Nicola Giuliani • 19 Apr 2018
1:39
Therapeutic options for smoldering myeloma
Nicola Giuliani • 19 Apr 2018

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals